Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 5:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: T1D Clear all
Completed Not applicable Interventional Results available

Effects of Micronutrient (Chromium) Supplementation on Diabetes

NCT01709123
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
chromium niacinate, placebo
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
8 Years to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 12, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Lactobacillus Plantarum as Therapy for NK-T Cell Deficiency

NCT00011141
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Oral lactobacillus administration
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
1 Year to 95 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 12, 2026, 5:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Matrix Metalloproteinases and Diabetic Nephropathy

NCT00067886
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetic Nephropathy
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
14 Years to 40 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Sep 12, 2026, 5:59 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of 18 F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass

NCT02236754
View directory record Official record
Conditions
Healthy Volunteers, Diabetes Mellitus, Type 1
Interventions
18 F-FP-DTBZ, PET Scanning
Drug · Radiation
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 12, 2026, 5:59 PM EDT
Not yet recruiting Not applicable Interventional

Argus 2.0 Adoption Study

NCT07425236
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 2, Prediabetes
Interventions
KOS Argus Continuous Glucose Monitoring System
Device
Lead sponsor
KOS Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 12, 2026, 5:59 PM EDT
Terminated Not applicable Interventional Results available

Using an Artificial Pancreas System in Older Adult Type 1 Diabetes Mellitus Patients

NCT03353792
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
CL/AP system, usual diabetic care
Device
Lead sponsor
Yale University
Other
Eligibility
50 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Sep 12, 2026, 5:59 PM EDT
Recruiting Phase 1 Interventional

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

NCT05065372
View directory record Official record
Conditions
Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
Interventions
Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo
Drug
Lead sponsor
Kalie Tommerdahl
Other
Eligibility
12 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 12, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes

NCT00982228
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
59
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 12, 2026, 5:59 PM EDT
Active, not recruiting Not applicable Interventional

Device Use Reimagined Through Education And Mentorship

NCT06546930
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
DREAM intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Davis, California • Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 12, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes

NCT02660242
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
G-Pen Mini™ (glucagon injection), Glucose Tabs, Basal Insulin Reduction
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Sep 12, 2026, 5:59 PM EDT
Not listed Not applicable Interventional

Mindfulness Training in Adolescents With Type 1 Diabetes

NCT06140030
View directory record Official record
Conditions
Anxiety, Type 1 Diabetes, Quality of Life
Interventions
Mindfulness training
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
12 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Sep 12, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional Results available

Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus

NCT03428945
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
37
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 12, 2026, 5:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

NCT05794581
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
CT-868, Placebo, Victoza
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 12, 2026, 5:59 PM EDT
Completed No phase listed Observational

Ability to Cope With Type 1 Diabetes

NCT00206349
View directory record Official record
Conditions
Depression
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 21 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 12, 2026, 5:59 PM EDT
Recruiting Not applicable Interventional

Diabetes Multimorbidity Typology, Trajectory, and Feasibility of an Audio Diary Mobile Application to Support Self-management

NCT07474376
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
Fabla Mobile App
Other
Lead sponsor
Emory University
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 12, 2026, 5:59 PM EDT
Recruiting Not applicable Interventional

EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes

NCT06014879
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Type 1 Doing Well (T1DW) Program, Diabetes-Related Information and Resources Program
Behavioral · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years to 99 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 12, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1

NCT00239148
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
E1 and G1
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
5
States / cities
Anniston, Alabama • Walnut Creek, California • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Sep 12, 2026, 5:59 PM EDT
Recruiting Not applicable Interventional

Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes

NCT07599982
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
Interventions
MODI Algorithm
Device
Lead sponsor
DreaMed Diabetes
Industry
Eligibility
18 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Baltimore, Maryland • Detroit, Michigan • Albany, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 12, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional Results available

Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes

NCT00837759
View directory record Official record
Conditions
Diabetes Mellitus Type 1, Autoimmune Diabetes
Interventions
Insulin, Lansoprazole, Sitagliptin, Diamyd, GAD65 (Diamyd)
Drug · Biological
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
16 Years to 30 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Sep 12, 2026, 5:59 PM EDT
Terminated Early Phase 1 Interventional

Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?

NCT01954459
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insupatch, Continuous glucose sensor
Device
Lead sponsor
Yale University
Other
Eligibility
8 Years to 44 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Sep 12, 2026, 5:59 PM EDT
Not listed No phase listed Observational

DKA Optic Ultrasound

NCT02130180
View directory record Official record
Conditions
Diabetic Ketoacidosis, Uncontrolled Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
7 Years to 18 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis and Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Sep 12, 2026, 5:59 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia

NCT02700048
View directory record Official record
Conditions
Hypoglycemia Unawareness, Type 1 Diabetes
Interventions
intra-nasal naloxone, Intra-nasal saline
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Sep 12, 2026, 5:59 PM EDT
Completed Not applicable Interventional Results available

Accelerometer Use in the Prevention of Exercise-Associated Hypoglycemia in Type 1 Diabetes: Outpatient Exercise Protocol

NCT02047643
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Computer algorithm to initiate pump suspension
Device
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 25 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Sep 12, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

NCT02414958
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
34
States / cities
Escondido, California • Huntington Beach, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Sep 12, 2026, 5:59 PM EDT